[go: up one dir, main page]

WO2006033912B1 - Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette - Google Patents

Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette

Info

Publication number
WO2006033912B1
WO2006033912B1 PCT/US2005/032706 US2005032706W WO2006033912B1 WO 2006033912 B1 WO2006033912 B1 WO 2006033912B1 US 2005032706 W US2005032706 W US 2005032706W WO 2006033912 B1 WO2006033912 B1 WO 2006033912B1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
day
bone mass
pthrp
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/032706
Other languages
English (en)
Other versions
WO2006033912A3 (fr
WO2006033912A2 (fr
Inventor
Andrew F Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osteotrophin LLC
Original Assignee
Osteotrophin LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteotrophin LLC filed Critical Osteotrophin LLC
Priority to AU2005287139A priority Critical patent/AU2005287139A1/en
Priority to EP05797693A priority patent/EP1799240A4/fr
Priority to MX2007003185A priority patent/MX2007003185A/es
Priority to CA002580281A priority patent/CA2580281A1/fr
Priority to JP2007532415A priority patent/JP2008513459A/ja
Publication of WO2006033912A2 publication Critical patent/WO2006033912A2/fr
Publication of WO2006033912A3 publication Critical patent/WO2006033912A3/fr
Publication of WO2006033912B1 publication Critical patent/WO2006033912B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes de prévention et de traitement de diverses maladies touchant les mammifères se manifestant par une perte de la masse osseuse, telles que l'ostéoporose. L'invention concerne des méthodes utilisant PTHrP (protéine liée à l'hormone parathyroïde) ou des analogues de celles-ci, qui sont à la fois efficaces et plus sûrs, dans le traitement des affections osseuses métaboliques.
PCT/US2005/032706 2004-09-16 2005-09-14 Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette Ceased WO2006033912A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005287139A AU2005287139A1 (en) 2004-09-16 2005-09-14 Treatment of bone disorders with skeletal anabolic drugs
EP05797693A EP1799240A4 (fr) 2004-09-16 2005-09-14 Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette
MX2007003185A MX2007003185A (es) 2004-09-16 2005-09-14 Tratamiento de trastornos oseos con farmacos anabolicos esqueletales.
CA002580281A CA2580281A1 (fr) 2004-09-16 2005-09-14 Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette
JP2007532415A JP2008513459A (ja) 2004-09-16 2005-09-14 骨同化物質を用いた骨疾患の治療方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61028304P 2004-09-16 2004-09-16
US60/610,283 2004-09-16

Publications (3)

Publication Number Publication Date
WO2006033912A2 WO2006033912A2 (fr) 2006-03-30
WO2006033912A3 WO2006033912A3 (fr) 2006-06-29
WO2006033912B1 true WO2006033912B1 (fr) 2006-09-08

Family

ID=36090476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032706 Ceased WO2006033912A2 (fr) 2004-09-16 2005-09-14 Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette

Country Status (6)

Country Link
EP (1) EP1799240A4 (fr)
JP (1) JP2008513459A (fr)
AU (1) AU2005287139A1 (fr)
CA (1) CA2580281A1 (fr)
MX (1) MX2007003185A (fr)
WO (1) WO2006033912A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346714B (es) * 2007-08-01 2017-03-24 The General Hospital Corp * Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
WO2011143406A2 (fr) 2010-05-13 2011-11-17 The General Hospital Corporation Analogues de l'hormone parathyroïdienne et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015195B2 (en) * 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US7906480B2 (en) * 2002-05-23 2011-03-15 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Also Published As

Publication number Publication date
JP2008513459A (ja) 2008-05-01
EP1799240A4 (fr) 2009-07-22
CA2580281A1 (fr) 2006-03-30
AU2005287139A1 (en) 2006-03-30
MX2007003185A (es) 2007-10-16
EP1799240A2 (fr) 2007-06-27
WO2006033912A3 (fr) 2006-06-29
WO2006033912A2 (fr) 2006-03-30

Similar Documents

Publication Publication Date Title
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
JP2014139220A5 (fr)
WO2003059291A3 (fr) Traitement des affections osseuses avec des medicaments anabolisants du squelette
TW200838545A (en) Therapeutic agent for painful disease
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
MXPA04012998A (es) Modulares de receptores nucleares de hormonas esteroideas triciclicos.
DE60041147D1 (de) Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen
CA2294101A1 (fr) Preparation pharmaceutique combinee contenant une parathormone et un inhibiteur de resorption osseuse
CA2212996A1 (fr) Procede de diminution des risques de fractures osseuses autres que les fractures vertebrales
TW200603816A (en) Risedronate compositions and their methods of use
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
CA2497353A1 (fr) Methode de prevention ou de reduction de fractures secondaires consecutives a une fracture de la hanche
WO2006033912B1 (fr) Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette
Verhaar et al. PTH-analogs: comparable or different?
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
WO2002005801A3 (fr) Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
WO2007139433A8 (fr) Substance peptidique normalisant le métabolisme dans les tissus osseux et cartilagineux, composition pharmaceutique à base de ladite substance et procédé d'application afférent
Gombotz et al. Opiate sparing effect of fixed combination of diclophenac and orphenadrine after unilateral total hip arthroplasty: A double-blind, randomized, placebo-controlled, multi-centre clinical trial
JP4931306B2 (ja) 骨形成を安全に促進させる医薬複合剤
PL371264A1 (en) Method for the treatment of bone disorders
Streifler et al. Calcitonin for pseudoclaudication in lumbar spinal stenosis
US20210196708A1 (en) Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
JP5300943B2 (ja) 骨形成を安全に促進させる医薬複合剤
TW200608965A (en) Medicine for prevention or treatment of diabetes
Lin et al. Parathyroid hormone for osteoporosis treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2580281

Country of ref document: CA

Ref document number: 2005287139

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003185

Country of ref document: MX

Ref document number: 2007532415

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2005287139

Country of ref document: AU

Date of ref document: 20050914

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005287139

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1236/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005797693

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005797693

Country of ref document: EP